Department of Transplantation, Renal Unit, Guy's Hospital, London, SE1 9RT, UK.
Pediatr Nephrol. 2013 Jul;28(7):1037-40. doi: 10.1007/s00467-012-2279-5. Epub 2012 Sep 2.
Long-term outcomes for paediatric renal transplant recipients have improved over the last 20 years, with better patient and renal allograft survival. As paediatric renal transplantation programmes have increased over this timeframe, living donation has become the favoured modality for renal replacement therapy and is advocated pre-emptively in as many cases as possible. However, one of the main barriers historically to living donation has been ABO blood-group incompatibility, with the result that patients were listed to be on call for a deceased donor renal transplant. The clinical scenario has now changed so that donors and recipients for renal transplantation can be worked up and listed for paired exchange and/or living-related ABO blood-group-incompatible renal transplantation (ABOi). There is extensive data in adult practice, and increasing evidence in paediatric practice that the short- and medium-term outcomes for both patient and renal allograft survival for ABOi is equivalent to that of blood-group-compatible renal transplantation.
在过去的 20 年中，儿科肾移植受者的长期预后得到了改善，患者和肾移植的存活率都有所提高。随着儿科肾移植项目在这段时间内的增加，活体捐赠已成为肾替代治疗的首选方式，并在尽可能多的情况下被预先提倡。然而，活体捐赠的一个主要障碍一直是 ABO 血型不相容，结果是患者被列入名单，以备接受已故供体的肾移植。目前的临床情况已经发生了变化，因此可以对肾移植的供体和受者进行检查，并将其列入配对交换和/或活体相关 ABO 血型不相容的肾移植（ABOi）的名单。在成人实践中有广泛的数据，在儿科实践中也有越来越多的证据表明，ABOi 的患者和肾移植的短期和中期结果与血型相容的肾移植相当。
